Vatalanib

DB04879

small molecule investigational

Deskripsi

Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

Struktur Molekul 2D

Berat 346.813
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 6 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapid onset of absorption

Metabolisme

Mainly through oxidative metabolism. Two pharmacologically inactive metabolites, CGP 84368/ZK 260120 and NVP AAW378/ZK 261557, having systemic exposure comparable to that of vatalanib, contributed mainly to the total systemic exposure.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

27 Data
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Vatalanib.
Propacetamol The serum concentration of Propacetamol can be increased when it is combined with Vatalanib.
Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Vatalanib.
Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Vatalanib.
Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.
Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Vatalanib.
Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Vatalanib.
Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Vatalanib.
Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vatalanib.
Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Vatalanib.
Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Vatalanib.
3,5-Diiodotyrosine The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Vatalanib.
Tiratricol The therapeutic efficacy of Tiratricol can be decreased when used in combination with Vatalanib.
Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Vatalanib.
Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Vatalanib.
Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Vatalanib.
Dibromotyrosine The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Vatalanib.
Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Vatalanib.
Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Vatalanib.
Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Vatalanib.
3,5-diiodothyropropionic acid The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vatalanib.
Methylthiouracil The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Vatalanib.
Elcatonin The therapeutic efficacy of Elcatonin can be decreased when used in combination with Vatalanib.
Benzylthiouracil The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Vatalanib.
Thyrotropin The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Vatalanib.
Voriconazole The serum concentration of Vatalanib can be increased when it is combined with Voriconazole.
Palopegteriparatide The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Vatalanib.

Target Protein

Epidermal growth factor receptor EGFR
Vascular endothelial growth factor receptor 3 FLT4
Vascular endothelial growth factor receptor 2 KDR
Vascular endothelial growth factor receptor 1 FLT1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17584317
    Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29.
  • PMID: 17616257
    Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15.
  • PMID: 16882767
    Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul